WILEX is a biopharmaceutical company and develops drugs based on antibodies
and small molecules with a low side effect profile and targeted treatment of
different types of cancer as well as diagnostic agents for specific detection
of tumours. WILEX’ aim is to help oncologists administer targeted treatments
to carefully diagnosed patients and to enhance patients' quality of life.
14.04.2014: WILEX published 3-Month Financial Report 2014....More
10.04.2014: WILEX plans capital reduction....More
Seite gelesen: 129904 | Heute: 236